A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial

Yan, ZL; Cao, J; Cheng, H; Qiao, JL; Zhang, HX; Wang, Y; Shi, M; Lan, JP; Fei, XM; Jin, L; Jing, GJ; Sang, W; Zhu, F; Chen, W; Wu, QY; Yao, Y; Wang, G; Zhao, J; Zheng, JN; Li, ZY; Xu, KL

Xu, KL (reprint author), Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China.

LANCET HAEMATOLOGY, 2019; 6 (10): E521

Abstract

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been shown to have activity in patients with relap......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索